

TRADE SECRET

Study Title

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

Laboratory Project ID: DuPont-11561

AUTHOR: Carol Finlay, B.A.

STUDY COMPLETED ON: April 7, 2003

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

WORK REQUEST NUMBER:



SERVICE CODE NUMBER:



Company Sanitized. Does not contain TSCA CBI

CERTIFICATION

We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.

Reviewed by: Paul M. Hinderliter 07-Apr-03
Paul M. Hinderliter, Ph.D.
Research Toxicologist
Date

Issued by Study Director: Carol Finlay 07-Apr-03
Carol Finlay, B.A.
Staff Toxicologist
Date

Company Sanitized. Does not contain TSCA CBI

TABLE OF CONTENTS

	Page
CERTIFICATION	2
LIST OF TABLES	4
LIST OF FIGURES	4
LIST OF APPENDICES	5
STUDY INFORMATION	6
STUDY PERSONNEL	8
SUMMARY	9
INTRODUCTION	11
MATERIALS AND METHODS	11
A. Test Substance and Positive Controls	11
B. Test Species	11
C. Animal Husbandry	11
D. Quarantine and Pretest	12
E. Study Design	13
F. Assignment to Groups and Study Start	13
G. Dosing Material Preparation and Administration	13
H. Body Weights	14
I. Mortality and Clinical Observations	14
J. Collection and Analysis of Blood, Livers, and Fat	14
K. Treatment of Fluorine Data	15
L. Statistical Analyses	16
RESULTS AND DISCUSSION	17
A. In-Life Toxicology	17
B. Liver Weights	17
C. Fluorine Data	18
CONCLUSIONS	19
RECORDS AND SAMPLE STORAGE	20
TABLES	21
FIGURES	28
APPENDICES	39

Company Sanitized. Does not contain TSCA CBI

LIST OF TABLES

	Page
1. MEAN BODY WEIGHTS.....	22
2. MEAN BODY WEIGHT GAINS.....	23
3. MEAN BODY AND LIVER WEIGHTS.....	24
4. MEAN BLOOD FLUORINE LEVELS.....	25
5. MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	25
6. MEAN LIVER FLUORINE LEVELS.....	26
7. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	26
8. MEAN FAT FLUORINE LEVELS.....	27
9. MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	27

LIST OF FIGURES

	Page
1. MEAN BODY WEIGHTS.....	29
2. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND NEGATIVE CONTROL.....	30
3. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND POSITIVE CONTROLS.....	31
4. MICROMOLAR EQUIVALENTS IN RAT BLOOD.....	32
5. NORMALIZED H-24750 AND POSITIVE CONTROL BLOOD AUCINF/D RESULTING FROM A 10-DAY ORAL GAVAGE.....	34
6. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	35
7. COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION FOR H-24750 AND NEGATIVE CONTROL.....	36
8. MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	37
9. COMPARISON OF MEAN BLOOD, MEAN LIVER, AND MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	38

Company Sanitized. Does not contain TSCA CBI

LIST OF APPENDICES

	Page
A. APPENDIX A INDIVIDUAL BODY WEIGHTS.....	40
B. APPENDIX B INDIVIDUAL CLINICAL OBSERVATIONS	50
C. APPENDIX C TERMS AND CALCULATIONS FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS	64
D. APPENDIX D INDIVIDUAL FLUORINE LEVELS IN BLOOD.....	68
E. APPENDIX E INDIVIDUAL FLUORINE LEVELS IN LIVER	75
F. APPENDIX F INDIVIDUAL FLUORINE LEVELS IN FAT	79

Company Sanitized. Does not contain TSCA CBI

STUDY INFORMATION

Test Substance

9th Collective Nomenclature: [REDACTED]

Synonyms/Codes: [REDACTED]

• H-24750

Submitter's Notebook Number(s) [REDACTED]

Haskell Number: 24750

CAS Registry Number: [REDACTED]

Purity: [REDACTED]

Known Impurities: [REDACTED]

Positive Control

Substance Tested: Potassium perfluoroalkyl sulfonate

Synonyms/Codes: • H-24019

• PFOS

Haskell Number: 24019

Composition: [REDACTED]

Known Impurities: [REDACTED]

Company Sanitized. Does not contain TSCA CBI

STUDY INFORMATION (Continued)

Positive Control

Substance Tested: Octanoic acid, pentadecafluoro-, ammonium salt

Synonyms/Codes: • H-24020

[REDACTED]

- C-8
- Perfluorooctanoate, ammonium salt
- APFO
- Ammonium perfluorooctanoate

Haskell Number: 24020

Composition:

[REDACTED]

Known Impurities:

[REDACTED]

Sponsor: E.I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.

Study Initiated/Completed: October 10, 2002 / (see report cover page)

Company Sanitized. Does not contain TSCA CBI

STUDY PERSONNEL

Study Director: Carol Finlay, B.A.

Management: Scott E. Loveless, Ph.D.

Primary Technician: James C. Mackay II

Fluorine Data Analysis: Paul M. Hinderliter, Ph.D.

Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T.

Toxicology Report Preparation: Sean M. Callaghan, B.A.

Management: Nancy S. Selzer, M.S.

Laboratory Veterinarian: Thomas W. Mayer, D.V.M., A.C.L.A.M.

SUMMARY

The objective of this study was to evaluate the potential for H-24750 to be absorbed and to accumulate in a mammalian system. Two groups of 5 male rats each were dosed by gavage with 5 mg/kg/day of H-24750 for 10 consecutive days. One group was sacrificed on Day 10, and the other group was maintained without dosing for an additional 84 days. Blood was collected on test days 1, 5, 10, 13, 24, 52, and 94. Livers and fat were collected at sacrifice. Body weights and clinical signs were recorded throughout the dosing and recovery periods. Additionally, a negative control of deionized water, and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested as described for H-24750. Blood, liver, and fat samples were analyzed for total fluorine content to determine test substance absorption and retention in these tissues.

No deaths occurred in rats treated with the test substance, H-24750. Several clinical signs and body weight effects were evident as a result of dosing with H-24750. One rat exhibited red nasal discharge during the recovery period, two exhibited hair loss during the recovery period, and one exhibited hair loss during the dosing and recovery period. The mean body weight gains of rats dosed with H-24750 were lower than the negative control rats during the dosing and recovery periods. Mean body weight gain of rats dosed with the positive control materials was similar during the dosing period to the weight gain of rats dosed with the test substance. During the recovery period, the mean body weight gain of rats dosed with the positive control materials was higher than the weight gain of rats dosed with the test substance.

For the purpose of comparing absorption and retention of the test substance to the positive controls, all doses were normalized on a molar basis. The total fluorine in each tissue was considered as a percentage of the fluorine delivered in the administered dose, and all units were expressed as μM equivalents. As a measure of total dose in the blood, an area under the curve (estimated to infinity) was calculated for each test material. The AUCINF/D for the fluorine component of H-24750 was 4.83×10^5 , compared to AUCINF/D values of 5.22×10^5 and 8.15×10^4 for H-24019 and H-24020, respectively. This parameter indicated a total dose in blood for H-24750 that was similar to or greater than the positive controls.

The mean relative liver weight (liver/body weight) of rats dosed with H-24750 was 62% higher than the negative control rats on day 10. By day 94, the mean relative liver weight of rats dosed with H-24750 was 23% higher than the negative control rats. The mean relative liver weight of rats dosed with H-24019 was 41% higher and for H-24020 was 93% higher on day 10 than the negative control group. By day 94, the mean relative liver weights of rats dosed with H-24019 and H-24020 were similar to the negative control group. Therefore, liver weights of rats dosed with the test substance were higher than negative controls at both the end of the dosing period and at the end of the recovery period.

The concentration of fluorine in the livers from rats dosed with H-24750 was 5518.80 μM equivalents on day 10 and 1476.01 μM equivalents on day 94. The mean μM equivalent concentration of fluorine in the livers from rats dosed with the test substance was slightly higher

Company Sanitized. Does not contain TSCA CBI

on days 10 and 94 than the value for the positive control H-24019. The mean μM equivalent concentration of fluorine in the livers from rats dosed with the test substance was approximately 6x higher (end of dosing) or approximately 86x higher (end of recovery) than the concentration in the positive control H-24020. Therefore, rats treated with H-24750 absorbed and retained considerably more fluorine in the liver than rats treated with H-24019 or H-24020.

The fluorine concentration in the fat from rats dosed with the test substance was 99.15 μM equivalents on day 10. There was no detectable fluorine by day 94. The fluorine concentration of the positive control H-24019 was approximately 2x higher than H-24750 on day 10. The fluorine concentration of the test substance was approximately 2x higher on day 10 than the positive control H-24020. By day 94, there was no detectable fluorine in the fat from rats dosed with the positive control, H-24020. Therefore, some absorption of fluorine occurred in fat from rats dosed with the test substance.

Under the conditions of this study, fluorine was evident in the blood during the period of dosing with H-24750. Not all of the fluorine was eliminated by the end of the recovery period from the blood or liver. The amounts of fluorine in the livers from rats dosed with the test substance were higher than levels in the blood and fat. Fluorine levels in the blood and liver were comparable or higher than levels in rats dosed with H-24019. Fluorine levels in the liver and fat were considerably higher than levels in rats dosed with the positive control H-24020.

Company Sanitized. Does not contain TSCA CBT

INTRODUCTION

The objective of this study was to define the potential of H-24750 to be absorbed and to bioaccumulate in a mammalian system, as indicated by analytical determination of total fluorine in blood, liver, and fat. The test substance was compared to 2 positive controls that were materials previously shown to bioaccumulate in mammals.

The daily dosage of 5 mg/kg for the test substance was selected based on existing toxicity information and the results of a rangefinding study. Groups of five rats were dosed at 0 (control) or 20 mg/kg for 5 consecutive days. The rats dosed with the test substance had an overall body weight loss of 37 grams compared to a weight gain 28 grams for the control rats. The dosage of 5 mg/kg was chosen for the study and was expected to produce less than a 10% difference in mean body weight over 10 days when compared to the negative control.

MATERIALS AND METHODS

A. Test Substance and Positive Controls

The test substance, H-24750, was supplied by the sponsor as a white solid. The positive controls, H-24019 and H-24020, were supplied by the sponsor as white solids. The test substance and positive controls appeared to be stable under the conditions of the study. No evidence of instability, such as a change in color or physical state, was observed.

B. Test Species

Male Crl:CD[®](SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina. The Crl:CD[®](SD)IGS BR rat was selected on the basis of extensive experience with this strain and its suitability with respect to longevity, hardiness, and low incidence of spontaneous diseases.

C. Animal Husbandry

1. Housing Environment

Rats were housed singly in stainless steel, wire-mesh cages suspended above cage boards. Animal rooms were maintained on an approximate 12-hour light/dark cycle (fluorescent light) and at a temperature of $23 \pm 1^{\circ}\text{C}$ and a relative humidity of $50 \pm 10\%$.

Company Sanitized. Does not contain TSCA CBI

2. Feed and Water

Tap water was provided *ad libitum*. All rats were fed PMI[®] Nutrition International, LLC Certified Rodent LabDiet[®] 5002 chow. The feed is guaranteed by the manufacturer to meet specified nutritional requirements and to be free of specified contaminants.

3. Identification

Each rat was assigned a unique identification number which was recorded on a card affixed to the cage. The last 3 digits of the number were tattooed on the tail of each rat.

4. Health Monitoring Program

As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to ensure that contaminant levels are below those that would be expected to impact the scientific integrity of the study:

- Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants.
- Feed samples are analyzed for total bacterial, spore, and fungal counts.
- Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers.

Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study.

The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. Evaluation of these data did not indicate any conditions that affected the validity of the study.

D. Quarantine and Pretest

Upon arrival at Haskell Laboratory, the rats were removed from shipping cartons and quarantined for 6 days. The rats were weighed 3 times during the pretest period and examined daily for any clinically apparent signs of disease or injury. The rats were observed daily for mortality and signs of illness, injury, or abnormal behavior.

On the bases of acceptable body weight gains and freedom from clinically apparent signs of disease or injury, the rats were released from quarantine by the laboratory animal veterinarian or designee.

Company Sanitized. Does not contain TSCA CBI

E. Study Design

Substance	Vehicle	Dosage (mg/kg)	Number of Animals
Negative Control Deionized water	Not applicable	0	10
Positive Controls H-24019	Acetone/Corn Oil	10	10
H-24020	Acetone/Corn Oil	20	10
Test Substance H-24750	Deionized Water	5	10

F. Assignment to Groups and Study Start

After the quarantine period, the rats were selected on the bases of adequate body weight gain, freedom from any clinical signs of disease or injury. The selected rats were arbitrarily assigned to each group.

After assignment to groups, each rat was housed individually. The rats were 7 weeks of age at the time of dosing. Dosing began on test day 1.

Rats that were not assigned to the study were released for other laboratory purposes, or were sacrificed by carbon dioxide asphyxiation and discarded without pathology evaluation.

G. Dosing Material Preparation and Administration

1. Test Substance

H-24750 was suspended in deionized water. The amount of test substance each rat received was based on the body weight collected on each day of dosing and the suspension concentration. The rats were dosed at a volume of 1 mL/100 g of body weight. The mixture was stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity.

2. Positive Controls

It was necessary to dissolve H-24019 and H-24020 in acetone before suspending them in corn oil. The ratio of acetone to corn oil was 20:80. The amount each rat received was based on the body weight collected on each day of dosing and the suspension concentration. The rats were dosed at a volume 1 mL/100 g of body weight. The dosing preparations were stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity.

Company Sanitized. Does not contain TSCA CBI

3. Negative Control

Deionized water was chosen as the negative control. The rats were dosed at a volume of 1 mL/100 g of body weight. These rats were dosed in a separate room from the rats dosed with the test substance or positive controls.

H. Body Weights

All rats were weighed on each day of dosing and weekly during the recovery period.

I. Mortality and Clinical Observations

Cage-site examinations to detect moribund or dead rats and abnormal behavior and appearance among rats were conducted at least once daily throughout the study. At every weighing, each rat was individually handled and examined for abnormal behavior and appearance.

J. Collection and Analysis of Blood, Livers, and Fat

At time points selected for blood sampling other than sacrifice days, approximately 1 mL of blood was collected into EDTA tubes from the orbital sinus of each rat. Rats designated for sacrifice were euthanized by carbon dioxide anesthesia and exsanguination and blood, livers, and fat were collected according to the following schedules:

Group	Dosing Days	Tissue Collected	Sampling Time
I	1-10	Blood	Test day 1 (2 hours post dosing)
I	1-10	Blood	Test day 5 (2 hours post dosing)
I	1-10	Blood, Liver, and Fat	Test day 10 at sacrifice (2 hours post dosing)
III	1-10	Blood	Test day 13
III	1-10	Blood	Test day 24
III	1-10	Blood	Test day 52
III	1-10	Blood, Liver, and Fat	Test day 94

As much blood as possible was collected into EDTA tubes at sacrifice. The livers and fat were weighed. The fat weights were used for the calculation of fluorine levels. The liver weights were used for the calculation of fluorine levels and for the calculation of liver weight relative to total body weight. The blood from all rats was refrigerated and the livers were frozen. The livers and fat were appropriately packaged and shipped refrigerated to Jackson Laboratory, Deepwater, New Jersey where they were analyzed for total fluorine. The liver and fat samples remained frozen during shipping.

The total fluorine content of the blood and tissue samples was determined using a Wickbold torch combustion method, followed by analysis with a fluoride ion selective electrode. The samples were decomposed or volatilized in the presence of wet oxygen and swept through an oxy-hydrogen flame in a closed quartz apparatus. The combustion products were collected in an

Company Sanitized. Does not contain TSCA CB

aqueous absorbing solution and analyzed with a fluoride ion selective electrode. Kinetic analysis of the data received (ppm F in each sample) was performed by Haskell Laboratory personnel for evaluation of fluorine biopersistence.

K. Treatment of Fluorine Data

Since the test substance and positive controls had different toxicity profiles, it was not possible to administer a uniform mg/kg dose for all test materials. Properly conducted kinetic comparisons in situations with varied doses required the use of a normalized dose. The dose-normalization was conducted in μ molar units to accommodate test material molecular weight differences and was adjusted to an arbitrary normalized dose of 0.1 mmoles/kg.

H-24019 and H-24020 were used as positive controls and a dosing diluent was used as the negative control. The percent of fluorine and molecular weight of the test substance and positive controls were used as provided by the sponsor. The measured total fluorine values were used as received (ppm F) from Jackson Laboratory. For the Wickbold torch method, the background fluorine level is 0.2 ppm. This is the limit of detection (LOD) of this method and was subtracted from each sample. The limit of quantification (LOQ) for this method is 0.5 ppm, and any values listed as less than 0.5 ppm were excluded from further treatment.

Since the dosages and molecular weight for positive controls and test material differed, the data were converted from a mass to a molar basis. In addition, the data were standardized to a single reference dose to allow comparison between compounds of differing fluorine content. The doses were first converted from a mg of test material basis to millimoles of fluorine. Raw fluoride ion data (ppm F) were then normalized to a 0.1 millimole dose of active component. Finally the molar dosage and normalized concentration were combined to yield the μ molar (μ M) equivalents of active component in the tissue. Detailed calculations can be found in Appendix C. The μ M equivalents can be compared across compounds provided the considerations listed in Appendix C are observed.

Noncompartmental analysis was conducted on fluorine data derived from rats dosed with H-24750 and the positive controls using WinNonlin Version 4.0 software (Pharsight Corp, Mountain View, CA). WinNonlin software provided a means of computing derived pharmacokinetic parameters from experimental data. All analysis was calculated using the μ M equivalent in blood data.

The maximum observed concentration in blood was C_{max} (μ M equivalent). Biopersistence was assessed by quantifying terminal elimination blood half-life ($T_{1/2}$, days). The points included in determination of the $T_{1/2}$ were selected manually and included only points after apparent log-linear elimination was achieved. Internal exposure was determined by calculating the blood area-under-the-curve (AUC). AUC, which is simply the integral of blood concentration over time, is the most common means for expressing internal dose. With the calculated half-life, the AUC can be extrapolated to infinity (AUCINF) to reflect the elimination of the compound. AUCINF normalized to dose (AUCINF/D) can be used to compare the relative exposures of different compounds and dosages.

Company Sanitized. Does not contain TSCA CBI

L. Statistical Analyses

Descriptive statistics (e.g. mean, standard deviation) were used.

RESULTS AND DISCUSSION

A. In-Life Toxicology

(Tables 1-2, Figure 1, Appendices A-B)

No deaths occurred in rats dosed with the test substance, H-24750. One rat exhibited red nasal discharge during the recovery period, two exhibited hair loss during the recovery period, and one exhibited hair loss during the dosing and recovery period. The mean body weight gains of rats dosed with H-24750 were lower than the negative control rats during the dosing and recovery periods. Mean body weight gain of rats dosed with the test substance was comparable during the dosing period but lower during the recovery period than the weight gain of rats dosed with the positive control materials.

B. Liver Weights

(Table 3, Figures 2, 3, and 7)

1. Test Substance

The mean relative liver weight (liver/body weight) of rats dosed with H-24750 was 62% higher than the negative control rats on day 10. By day 94, the mean relative liver weight of rats dosed with H-24750 was 23% higher than the negative control rats.

2. Positive Controls

The mean relative liver weight of rats dosed with one of the positive controls, H-24019, was 15% lower at day 10 than the liver weight of rats dosed with H-24750. By day 94, the mean relative liver weight of rats dosed with H-24019 was 15% lower than the liver weight of rats dosed with H-24750.

The mean relative liver weight of rats dosed with the other positive control, H-24020, was 16% higher at day 10 than the liver weight of rats dosed with H-24750. By day 94, the mean relative liver weight of rats dosed with H-24020 was 21% lower than the liver weight of rats dosed with H-24750.

The mean relative liver weight of rats dosed with H-24019 was 38% higher at day 10 than the negative control group. By day 94, the mean relative liver weight of rats dosed with H-24019 was similar to the negative control group. The mean relative liver weight of rats dosed with H-24020 was 88% higher on day 10 than the negative control group. By day 94, the weights were similar.

Therefore, the relative liver weights of rats dosed with the test substance, H-24750, were higher than negative controls both at the end of the dosing period and at the end of the recovery period.

Company Sanitized. Does not contain TSCA CB

C. Fluorine Data
(Tables 4-9, Figures 4-9, Appendices C-F)

1. Factors Influencing Interpretation of Analysis

The data used in the kinetic analysis were derived from a limited screen, and therefore several caveats and considerations are important. A couple of considerations of particular importance are (1) a single dose was used and kinetics may or may not be linear, (2) the kinetics apply only to blood, (3) steady-state may not have been achieved, and (4) the sample size is low and may impact calculation of the terminal half-life. A more complete list of considerations is shown in Appendix C.

2. Positive Controls

The positive controls were H-24019 and H-24020. The H-24019 and H-24020 normalized μM equivalents in rat blood continued to rise throughout the dosing period and may not have reached steady-state (Figure 4A and 4B). The C_{max} for H-24019 was $1043.08 \pm 54.57 \mu\text{M}$ equivalents (mean $\pm$ S.D.) with a terminal half-life of 42.2 days. The C_{max} for H-24020 was $541.45 \pm 50.37 \mu\text{M}$ equivalents (mean $\pm$ S.D.) with a terminal half-life of 15.1 days. For each of the positive controls, blood was sampled at 7 time points throughout the study, with only 4 of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between positive controls and the test substance. The AUCINF/D for the fluorine component was 5.22×10^5 for H-24019 and 8.15×10^4 for H-24020.

The concentrations of fluorine in the livers on day 10 from rats dosed with the positive control materials were 4802.15 and 866.67 μM equivalents for H-24019 and H-24020, respectively. By day 94, the concentrations were 1292.92 and 17.10 μM equivalents.

The concentrations of fluorine in the fat on day 10 from rats dosed with the positive control materials were 194.46 and 57.25 μM equivalents for H-24019 and H-24020, respectively. By day 94, the concentration of fluorine in the fat from rats dosed with H-24019 was 15.38 μM equivalents. There was no detectable fluorine by day 94 in the fat from rats dosed with H-24020.

3. Test Substance

The H-24750 normalized uM equivalents in rat blood rose rapidly and did not reach steady-state (Figure 4C). The C_{max} for H-24750 was 974.25 ± 201.73 uM equivalents (Mean $\pm$ SD) with a terminal half-life of 31.1 days. Blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between H-24750 and positive controls. The AUCINF/D for the fluorine component of H-24750 was 4.83×10^5 as compared to AUCINF/D values of 5.22×10^5 and 8.15×10^4 for H-24019 and H-24020, respectively (Figure 4C).

Levels of total fluorine in livers from rats dosed with the test substance, H-24750, were higher than the levels in livers from rats dosed with the positive control materials. The total fluorine concentration in the liver from rats dosed with H-24750 was 5518.80 μ M equivalents at day 10 and 1476.01 μ M equivalents at day 94. The liver concentrations in rats dosed with H-24750 were somewhat higher on days 10 and 94 than the concentrations in rats dosed with the positive control material H-24019. The liver concentrations in rats dosed with H-24750 were approximately 6x higher (day 10) and 86x higher (day 94) than the concentrations in rats dosed with the positive control material H-24020.

Levels of total fluorine in fat from rats dosed with the test substance were lower than the levels in fat from rats dosed with the positive control material H-24019. However, the level on day 10 was higher in rats dosed with the test substance than in rats dosed with the other positive control, H-24020. The fluorine concentration in the fat from rats dosed with the test substance was 99.15 μ M equivalents on day 10. There was no detectable fluorine on day 94. The fluorine concentration of one of the positive control materials, H-24019, was approximately 2x higher than H-24750 on day 10. The fluorine concentration of the test substance was approximately 2x higher on day 10 than the other positive control material, H-24020. There was no detectable fluorine by day 94 in the fat from rats dosed with H-24020.

The uM equivalents in the liver of rats treated with H-24750 were higher than levels in the blood and fat.

CONCLUSIONS

Rats dosed for 10 consecutive days with 5 mg/kg H-24750 exhibited no mortality. Clinical signs and body weight effects were observed. Liver weights were affected in rats dosed with the test substance. A steady-state for fluorine in the blood was not achieved during the 10-day dosing period with the test substance. Dose-adjusted area under the curve (AUCINF/D) for the positive control H-24019 was similar to the AUCINF/D for the test substance. Dose-adjusted area under the curve (AUCINF/D) for the test substance was 6x the AUCINF/D for the positive control H-24020.

Company Sanitized. Does not contain TSCA CBI

Under the conditions of this study, there was considerable absorption and retention of fluorine in the blood following dosing with H-24750. Administration of the test substance, H-24750, to male rats for 10 consecutive days resulted in absorption and retention of fluorine in the liver. There was some absorption and little retention of fluorine in the fat. Levels in the fat in rats dosed with the test substance were lower than levels in the positive control material H-24019 but higher than levels in the positive control material H-24020.

RECORDS AND SAMPLE STORAGE

Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware.

Company Sanitized. Does not contain TSCA CBI

TABLES

Company Sanitized. Does not contain TSCA CBI

TABLE 1
MEAN BODY WEIGHTS

DAYS ON TEST	MEAN BODY WEIGHTS (g)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-24750
1	189.6	184.4	184.1	189.2
2	195.5	189.2	187.8	195.3
3	204.6	199.5	197.8	203.0
4	211.7	206.4	204.8	213.3
5	222.1	216.2	212.5	224.5
6	225.0	222.0	216.0	231.8
7	235.2	229.4	223.6	239.2
8	242.3	233.7	226.9	244.5
9	248.3	240.4	234.2	249.1
10	257.0	246.5	243.0	248.4
17	293.3	290.1	297.4	237.4
24	325.5	313.3	338.6	247.9
31	359.3	348.4	381.9	265.2
38	380.9	370.8	404.9	279.5
45	407.4	403.2	434.4	305.2
52	420.5	422.8	460.6	330.0
59	436.4	439.6	483.1	342.3
66	-	-	-	369.6
67	452.8	455.6	502.7	-
73	472.6	480.1	525.6	390.5
80	489.6	496.5	542.1	413.1
87	497.7	512.2	546.2	423.5
94	511.7	524.6	570.5	434.6

- Indicates the animals were not weighed

Company Sanitized. Does not contain TSCA CBI

TABLE 2
MEAN BODY WEIGHT GAINS

DOSING

DAYS ON TEST	MEAN BODY WEIGHT GAINS (g)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-24750
1-5	32.5	31.8	28.4	35.3
5-10	34.9	30.3	30.5	23.9
1-10	67.4	62.1	58.9	59.2

RECOVERY

DAYS ON TEST	MEAN BODY WEIGHT GAINS (g)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-24750
10-17	36.3	43.6	54.4	-11.1
17-24	32.2	23.2	41.2	10.5
24-52	95.0	109.5	122.0	82.1
52-94	91.2	101.8	109.9	104.6
10-94	254.7	278.1	327.5	186.2

Company Sanitized. Does not contain TSCA CB1

TABLE 3

MEAN BODY AND LIVER WEIGHTS

NEGATIVE CONTROL - DEIONIZED WATER			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	258.8	10.814	0.042
94	511.7	17.868	0.035

POSITIVE CONTROL - H-24019			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	243.9	14.205	0.058
94	524.6	19.296	0.037

POSITIVE CONTROL - H-24020			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	243.1	19.174	0.079
94	570.5	19.590	0.034

TEST SUBSTANCE - H-24750			
DAYS ON TEST	WEIGHT (g)		Mean Relative Liver Weight (Liver/Body Weight)
	Absolute		
	Body Weight	Liver Weight	
10	260.9	17.785	0.068
94	434.6	18.841	0.043

Company Sanitized. Does not contain TSCA CBI

TABLE 4
MEAN BLOOD FLUORINE LEVELS

DAYS ON TEST	MEAN FLUORINE LEVELS (ppm)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-24750
1	0.60 ^a	2.60 (0.1) ^b	9.40 (2.4)	3.14 (0.32)
5	- ^c	31.32 (1.1)	74.92 (7.0)	17.13 (2.22)
10	1.10 ^a	68.00 (3.5)	61.76 (5.5)	30.44 (1.22)
13	- ^c	53.98 (1.2)	29.52 (4.9)	34.40 (7.08)
24	0.5 ^a	39.62 (3.4)	11.18 (2.9)	27.60 (4.21)
52	- ^c	23.56 (2.1)	2.26 (1.1)	9.30 (2.78)
94	- ^c	12.60 (1.2)	0.85 ^d (0.1)	6.24 (0.46)

- a One of 5 values. Four of the values were below the limit of quantification (LOQ) or non-detectable.
b Standard deviation (S.D.) is in parentheses.
c All values were below the LOQ or non-detectable.
d Mean of 2 of the 5 values. Three of the values were below the LOQ.

TABLE 5
MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE

DAYS ON TEST	MEAN FLUORINE CONCENTRATION (μ M F Equivalents)		
	Positive Controls		Test Substance
	H-24019	H-24020	H-24750
1	36.92 (1.1) ^a	66.67 (17.5)	83.70 (9.07)
5	478.77 (17.6)	541.45 (50.4)	482.39 (63.24)
10	1043.08 (54.6)	446.09 (39.7)	861.42 (34.76)
13	827.38 (19.0)	212.46 (35.6)	974.25 (201.73)
24	606.46 (53.1)	79.57 (20.8)	780.68 (120.05)
52	359.38 (32.7)	14.93 (7.7)	259.15 (79.34)
94	190.77 (19.2)	4.71 ^b (0.5)	172.14 (13.23)

- a Standard deviation (S.D.) is in parentheses.
b Mean of 2 of the 5 values. Three of the values were below the limit of quantification (LOQ).

Company Sanitized. Does not contain TSCA CBI

TABLE 6
MEAN LIVER FLUORINE LEVELS

DAYS ON TEST	MEAN FLUORINE LEVELS (ppm)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-24750
10	0.90 (0.2) ^a	312.34 (19.7)	119.80 (3.5)	193.91 (7.17)
94	0.78 (0.0)	84.24 (7.4)	2.56 (1.3)	52.01 (5.26)

a Standard deviation (S.D.) is in parentheses.

TABLE 7
MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE

DAYS ON TEST	MEAN FLUORINE CONCENTRATION (μM F Equivalents)		
	Positive Controls		Test Substance
	H-24019	H-24020	H-24750
10	4802.15 (303.8) ^a	866.67 (25.5)	5518.80 (204.34)
94	1292.92 (114.1)	17.10 (9.8)	1476.01 (149.92)

a Standard deviation (S.D.) is in parentheses.

Company Sanitized. Does not contain TSCA CBI

TABLE 8

MEAN FAT FLUORINE LEVELS

DAYS ON TEST	MEAN FLUORINE LEVELS (ppm)			
	Negative Control	Positive Controls		Test Substance
	Deionized Water	H-24019	H-24020	H-24750
10	- ^a	12.84 (1.7) ^b	8.10 (1.1)	3.68 (0.6)
94	- ^a	1.20 (0.3)	- ^a	- ^a

a All values were below the limit of quantification (LOQ) or non-detectable.

b Standard deviation (S.D.) is in parentheses.

TABLE 9

MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE

DAYS ON TEST	MEAN FLUORINE CONCENTRATION (μM F Equivalents)		
	Positive Controls		Test Substance
	H-24019	H-24020	H-24750
10	194.46 (26.8) ^a	57.25 (7.8)	99.15 (17.1)
94	15.38 (4.1)	- ^b	- ^b

a Standard deviation (S.D.) is in parentheses.

b All values were below the limit of quantification (LOQ) or non-detectable.

Company Sanitized. Does not contain TSCA CBI

FIGURES

Company Sanitized. Does not contain TSCA CBI

FIGURE 1
MEAN BODY WEIGHTS





FIGURE 2
COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND NEGATIVE CONTROL



Company Sanitized. Does not contain TSCA CBI

FIGURE 3
COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND POSITIVE CONTROLS





FIGURE 4


MICROMOLAR EQUIVALENTS IN RAT BLOOD

A. Normalized Rat Blood H-24019 μ M Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μ M) equivalents of H-24019 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.


B. Normalized Rat Blood H-24020 μ M Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μ M) equivalents of H-24020 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

Company Sanitized. Does not contain TSCA CBI


C. Normalized Rat Blood H-24750 μM Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μM) equivalents of H-24750 (test substance) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 5
NORMALIZED H-24750 AND POSITIVE CONTROL BLOOD AUCINF/D
RESULTING FROM A 10-DAY ORAL GAVAGE



Company Sanitized. Does not contain TSCA CBI

FIGURE 6

MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE





FIGURE 7

COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION
FOR H-24750 AND NEGATIVE CONTROL



- Deionized Water (Negative Control)
- H-24750 (Test Substance)

FIGURE 8
MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE





FIGURE 9

COMPARISON OF MEAN BLOOD, MEAN LIVER, AND MEAN FAT FLUORINE
CONCENTRATION NORMALIZED TO DOSE



APPENDICES

Company Sanitized. Does not contain TSCA CBI

APPENDIX A

Individual Body Weights

Company Sanitized. Does not contain TSCA CBI

INDIVIDUAL BODY WEIGHTS

EXPLANATORY NOTES

ABBREVIATIONS:

SD - sacrificed by design

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

DEIONIZED WATER (NEGATIVE CONTROL)
INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646932	197.1	202.1	212.9	221.5	233.6	234.1	242.4	251.1	256.1
646933	191.9	195.4	205.0	213.2	226.5	219.3	232.9	239.5	246.4
646934	182.6	188.9	195.4	207.0	213.9	215.9	224.2	230.9	238.1
646935	203.0	208.9	218.0	228.1	239.7	243.0	257.2	265.7	270.5
646936	196.8	201.4	208.6	204.0	216.7	218.6	229.9	234.9	240.3

TEST DAY

ANIMAL
NUMBER

Day 10

646932	264.7	SD test day 10
646933	254.4	SD test day 10
646934	248.6	SD test day 10
646935	278.0	SD test day 10
646936	248.1	SD test day 10

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	Day 1	Day 2	Day 3	Day 4	TEST DAY		Day 6	Day 7	Day 8	Day 9
					Day 5	Day 5				
646937	184.5	186.8	199.0	205.9	213.6	213.6	221.0	229.6	238.7	241.4
646938	163.7	173.8	180.9	189.3	200.6	200.6	204.1	215.9	221.8	228.3
646939	193.3	204.2	214.6	221.1	234.4	234.4	240.7	248.9	259.2	267.3
646940	191.5	197.1	203.8	209.8	218.5	218.5	222.1	229.3	232.0	237.5
646941	191.6	195.9	207.9	216.8	223.1	223.1	231.2	241.3	249.1	257.0

ANIMAL NUMBER	Day 10	Day 17	Day 24	Day 31	TEST DAY		Day 45	Day 52	Day 59	Day 67
					Day 38	Day 38				
646937	249.8	282.6	322.3	366.1	395.0	395.0	425.0	443.9	461.7	478.7
646938	237.2	270.4	296.5	325.8	342.9	342.9	367.5	373.7	378.7	401.3
646939	277.9	329.7	372.8	415.2	443.2	443.2	475.2	484.1	505.7	516.4
646940	244.5	271.5	291.3	317.9	332.8	332.8	356.3	367.0	380.3	392.5
646941	266.3	312.4	344.8	371.6	390.7	390.7	412.8	433.6	455.8	475.3

ANIMAL NUMBER	Day 73	Day 80	Day 87	Day 94	TEST DAY	
					Day 94	Day 94
646937	504.3	520.5	533.7	545.7	SD test day 94	SD test day 94
646938	417.4	431.0	432.1	450.6	SD test day 94	SD test day 94
646939	540.1	568.9	578.1	586.9	SD test day 94	SD test day 94
646940	407.3	424.0	430.8	449.4	SD test day 94	SD test day 94
646941	493.7	503.5	513.8	525.8	SD test day 94	SD test day 94

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

H-24019 (POSITIVE CONTROL)
INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

ANIMAL NUMBER	GROUP I								
	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646910	184.3	185.3	197.3	204.8	212.7	216.3	226.4	232.3	237.5
646911	184.4	187.1	195.7	202.0	211.7	217.2	225.2	225.6	231.9
646912	180.5	185.9	195.9	202.5	211.9	217.7	227.2	232.4	238.5
646913	186.4	189.7	198.1	205.7	221.8	225.0	228.6	238.4	245.8
646914	185.5	189.6	198.8	203.8	215.4	222.7	226.7	231.5	238.8

TEST DAY

ANIMAL
NUMBER

Day 10

646910	241.1	SD test day 10
646911	236.6	SD test day 10
646912	241.9	SD test day 10
646913	257.0	SD test day 10
646914	243.0	SD test day 10

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

H-24019 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646915	182.7	188.3	200.1	206.3	211.1	220.6	225.8	231.1	236.8
646916	185.0	192.7	205.5	211.6	220.0	226.9	239.5	240.1	249.3
646917	187.8	194.3	205.8	210.4	221.8	227.5	233.9	235.8	244.3
646918	175.5	181.9	189.8	197.6	207.0	212.4	220.2	224.1	228.2
646919	192.0	196.9	207.9	218.9	228.3	234.0	240.8	245.8	252.9

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646915	240.4	283.4	302.9	326.7	337.9	371.1	399.7	412.5	433.1
646916	257.0	310.0	334.4	383.2	411.9	450.3	469.8	494.8	511.8
646917	250.2	280.3	308.2	339.7	362.8	387.9	409.0	420.0	441.5
646918	237.1	270.6	292.7	323.2	350.8	379.4	396.7	418.8	433.8
646919	260.2	306.1	328.5	369.2	390.4	427.3	439.0	451.7	457.6

ANIMAL NUMBER	TEST DAY								
	Day 73	Day 80	Day 87	Day 94	SD test day 94	SD test day 94	SD test day 94	SD test day 94	SD test day 94
646915	461.2	475.0	498.1	513.3	513.3	590.9	578.5	479.5	480.8
646916	544.2	565.5	578.5	590.9	590.9	495.7	479.5	500.3	522.9
646917	457.5	464.7	479.5	495.7	495.7	500.3	480.8	522.9	524.2
646918	448.1	472.5	480.8	500.3	500.3	522.9	524.2	524.2	524.2
646919	489.5	504.8	524.2	522.9	522.9	524.2	524.2	524.2	524.2

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

H-24020 (POSITIVE CONTROL)
INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

ANIMAL NUMBER	GROUP I								
	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646921	204.5	204.9	215.7	222.2	233.3	238.8	244.3	244.9	252.2
646922	178.3	180.9	188.9	197.4	197.7	202.4	202.4	204.0	207.7
646923	185.9	185.1	196.0	202.3	203.5	204.9	219.1	224.9	231.7
646924	188.7	194.6	209.5	212.6	230.4	225.9	236.2	236.5	250.9
646925	172.2	176.0	183.9	193.4	202.7	202.7	215.1	221.5	228.7

ANIMAL NUMBER	Day 10	TEST DAY
646921	262.6	SD test day 10
646922	218.6	SD test day 10
646923	240.6	SD test day 10
646924	259.1	SD test day 10
646925	234.8	SD test day 10

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

H-24020 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646926	182.0	187.8	197.0	203.6	206.0	213.2	222.9	229.9	239.7
646927	172.2	178.8	191.1	195.1	206.6	213.2	218.2	228.7	233.1
646928	190.4	195.3	204.5	212.3	222.1	230.1	236.1	235.8	243.4
646929	178.6	182.5	190.7	198.3	203.5	204.2	214.6	210.3	219.2
646930	187.9	191.6	201.0	210.4	219.6	224.4	226.7	232.6	235.3

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646926	250.8	297.2	349.3	383.8	412.1	432.1	467.8	493.2	509.5
646927	243.3	306.2	355.1	404.0	424.8	463.2	484.0	511.7	527.2
646928	254.1	310.6	349.4	392.8	422.4	443.5	464.8	492.2	518.6
646929	225.5	280.9	323.2	376.0	396.8	426.4	450.2	463.8	484.2
646930	240.3	292.3	316.2	352.7	368.4	406.8	436.0	454.7	474.2

ANIMAL NUMBER	TEST DAY			
	Day 73	Day 80	Day 87	Day 94
646926	535.3	551.9	564.4	580.6 SD test day 94
646927	551.2	574.5	541.3	602.5 SD test day 94
646928	540.3	557.0	568.3	581.9 SD test day 94
646929	502.6	509.6	526.7	544.0 SD test day 94
646930	498.5	517.6	530.3	543.4 SD test day 94

Company Sanitized. Does not contain TSCA CB1

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

H-24750 (TEST SUBSTANCE)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
665547	194.5	200.9	210.4	225.1	238.6	243.3	252.1	259.9	267.0
665548	191.6	195.8	202.5	211.7	225.5	231.3	238.6	244.3	246.4
665549	190.1	197.4	201.0	218.3	230.0	233.2	245.4	252.2	263.1
665550	193.0	196.6	204.9	218.8	230.0	241.4	248.4	259.5	266.2
665553	193.4	199.0	209.0	216.4	228.4	235.1	247.3	255.1	262.7

TEST DAY

ANIMAL
NUMBER

Day 10

665547	274.1	SD test day 10
665548	253.9	SD test day 10
665549	253.2	SD test day 10
665550	264.0	SD test day 10
665553	259.5	SD test day 10

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

H-24750 (TEST SUBSTANCE)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	Day 1	Day 2	Day 3	Day 4	TEST DAY		Day 7	Day 8	Day 9
					Day 5	Day 6			

665554	175.0	180.0	187.8	195.2	204.6	210.8	212.5	209.7	211.3
665555	184.9	194.4	201.6	208.7	217.6	230.9	240.0	247.4	247.0
665558	187.8	192.0	201.9	211.1	221.9	226.5	229.0	234.4	235.6
665559	189.2	196.6	204.2	213.4	222.9	230.8	240.7	243.6	246.8
665560	192.9	200.2	206.5	214.1	225.8	234.7	238.0	239.3	244.6

ANIMAL NUMBER	Day 10	Day 17	Day 24	Day 31	TEST DAY		Day 45	Day 52	Day 59	Day 67
					Day 38	Day 45				

665554	209.4	212.0	220.3	232.1	234.0	249.4	270.5	290.5	312.8
665555	254.7	247.7	255.3	275.0	281.7	316.0	340.3	353.6	369.3
665558	229.5	229.7	224.6	229.8	227.1	235.4	259.9	280.3	316.6
665559	239.5	243.9	257.8	271.8	305.8	336.1	370.2	380.4	400.6
665560	246.4	253.5	281.7	317.3	348.7	389.1	408.9	406.8	448.7

TEST DAY

ANIMAL NUMBER	Day 73	Day 80	Day 87	Day 94	TEST DAY	
					SD test day 94	SD test day 94

665554	330.1	355.1	368.3	380.2	SD test day 94	SD test day 94
665555	387.9	412.1	425.9	431.8	SD test day 94	SD test day 94
665558	345.4	366.1	373.1	381.2	SD test day 94	SD test day 94
665559	418.3	441.6	451.0	467.1	SD test day 94	SD test day 94
665560	470.9	490.5	499.3	512.5	SD test day 94	SD test day 94

Company Sanitized. Does not contain TSCA CBI

APPENDIX B
Individual Clinical Observations

Company Sanitized. Does not contain TSCA CBI

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646932	General observation, No Abnormality Detected	1
	Eye Observations, Exophthalmus, Left	2-9
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Discharge, Eye left, Black	10
	Sacrificed by design	10
646933	General observation, No Abnormality Detected	1-5
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Eye Observations, Dark, Left	6-10
	Discharge, Eye left, Black	6-7
	Swollen Observations, Mouth	10
	Sacrificed by design	10
646934	General observation, No Abnormality Detected	1-5,10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Discharge, Eye left, Black	6-9
	Sacrificed by design	10

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

DEIONIZED WATER (NEGATIVE CONTROL)		
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS		
GROUP I (Continued)		
Animal	Observation	Days
646935	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646936	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10

Company Sanitized. Does not contain TSCA CBI

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646937	General observation, No Abnormality Detected	1-10,17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24,52
	Sacrificed by design	94
646938	General observation, No Abnormality Detected	1-10,17-45
	Eye Observations, Enophthalmus, Right	80-94
	Eye Observations, Exophthalmus, Right	52-73
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	13,52
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Eye Observations, Corneal Opacity, Right	80-94
	Discharge, Eye right, Black	59
	Sacrificed by design	94
646939	General observation, No Abnormality Detected	1-10,17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24,52
	Sacrificed by design	94

Company Sanitized. Does not contain TSCA CBI

H-24750: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-11561

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646940	General observation, No Abnormality Detected	1-10, 17-80, 94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Discharge, Nose, Black	87
	Sacrificed by design	94
646941	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Sacrificed by design	94

Company Sanitized. Does not contain TSCA CB1

H-24019 (POSITIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646910	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646911	General observation, No Abnormality Detected	1,10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Eye Observations, Dark, Left	2-9
	Sacrificed by design	10
646912	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646913	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646914	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10

Company Sanitized. Does not contain TSCA CBI

H-24019 (POSITIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646915	General observation, No Abnormality Detected	1, 17-38, 73
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24, 52
	Discharge, Eye right, Red	2-10
	Hair Loss, Forelimb, Right	80
	Hair Loss, Forepaw, Right	45-67, 87-94
	Sacrificed by design	94
646916	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	24
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94
646917	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24019 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646918	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94
646919	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24020 (POSITIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646921	General observation, No Abnormality Detected	1, 5-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1, 5
	Eye Observations, Dark, Left	2-4
	Sacrificed by design	10
646922	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646923	General observation, No Abnormality Detected	1, 7-10
	Eye Observations, Exophthalmus, Left	4-6
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Eye Observations, Dark, Left	2-6
	Sacrificed by design	10

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I (Continued)

Animal	Observation	Days
646924	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646925	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10

H-24020 (POSITIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646926	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Sacrificed by design	94
646927	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Sacrificed by design	94
646928	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24, 52
	Sacrificed by design	94

Company Sanitized. Does not contain TSCA CBI

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646929	General observation, No Abnormality Detected	1-10, 17-31
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Hair Loss, Forelimb, Bilateral	52-73
	Hair Loss, Neck, Left	73
	Hair Loss, Neck, Ventral	38-67, 80-94
	Wound, Superficial, Face	59
	Sacrificed by design	94
646930	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24750 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
665547	General observation, No Abnormality Detected	1-109
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
665548	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
665549	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
665550	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10
665553	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Right	1,5
	Sacrificed by design	10

H-24750 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
665554	General observation, No Abnormality Detected	1-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24,52
665555	General observation, No Abnormality Detected	1-10
	Eye Observations, Closed	38-94
	Eye Observations, Exophthalmus, Right	17-31
	Eye Observations, Bled via Orbital for Clin Path, Left	24,52
	Discharge, Nose, Red	45
	Hair Loss, Face, Right	31-45
	Comments	17-94
665558	General observation, No Abnormality Detected	1-17,87-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24,52
	Hair Loss, Forelimb, Bilateral	24-80
	Hair Loss, Forepaw, Bilateral	24-66
665559	General observation, No Abnormality Detected	1-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24,52
665560	General observation, No Abnormality Detected	1-4,17-94
	Eye Observations, Bled via Orbital for Clin Path, Right	24,52
	Hair Loss, Shoulder, Bilateral	9-10
	Hair Loss, Shoulder, Left	5- Company Sanitized Does not contain TSCA CBI

APPENDIX C

Terms and Calculations Factors Influencing Interpretation of Kinetic Analysis

Company Sanitized. Does not contain TSCA CBI

TERMS AND CALCULATIONS

Terms:

Active	Fluorine containing compound
% Active	The % of formulation that is made up of fluorine containing components
Mol Wt Active	The molecular weight of the fluorine containing components (g/mole)
Formulation Dose	The mg of formulation given per kg of animal body weight
% F in Active	The % fluorine in the fluorine containing components of the formulation (weight basis)
Mol Wt F	The molecular weight of fluorine g/mol

Compound Calculations:

Dose Active (mg/kg)	The mg of fluorine containing compound administered per kg of animal body weight. $= (\% \text{ active}/100) \times \text{Formulation Dose}$
Dose Active (mmole/kg)	The mmole of fluorine containing compound administered per kg of animal body weight $= \text{dose [mg/kg]} / \text{Mol Wt Active [mg/mmol]}$
Dose F (mg/kg)	The mg Fluorine administered per kg of animal body weight $= (\% \text{ F in active}/100) \times \text{Dose Active [mg/kg]}$
Dose F (mmol/kg)	The mmole of fluorine administered per kg of animal body weight $= \text{Dose F [mg/kg]} / \text{Mol Wt F [mg/mmol]}$
Molar Ratio (Active/F)	The moles of fluorine containing compound per mole of fluorine $= \text{Dose Active [mmol/kg]} / \text{Dose F [mmol/kg]}$
Formulation Dose Normalization Factor	The formulation dose that would be required to administer the amount of active needed to achieve the normalized dose $= (\text{Normalized dose of Active [mmol/kg]} / \text{Dose Active [mmol/kg]}) \times \text{Formulation Dose}$

Company Sanitized. Does not contain TSCA CBI

TERMS AND CALCULATIONS

Individual Animal Measurement:

ppm F The ppm fluoride measured

Individual Animal Calculations:

ppm F minus
Bkg 0.2 ppm The ppm fluoride measured minus the background fluoride measured in control animal. In this case the value was established at 0.2 ppm.

ppm F
normalized to
0.1 mmol/kg Dose The ppm fluoride minus background that would be expected if the active dose was 0.1 mmol/kg instead of the actual active dose. This assumes linearity between administered dose and blood fluorine levels, but is needed because different doses of active were used in the study.
$$= (0.1 \text{ [mmol/kg]} / \text{Active dose [mmol/kg]}) \times (\text{ppm F in blood minus background})$$

μmolar equivalents of
active The μmolar [μmol/L] concentration of fluorine containing compound based on the ppm fluorine normalized to 0.1 mmol/kg active dose. This assumes that all fluorine is derived from the fluorine-containing component in the formulation. Note: 1 ppm – 1 mg/L
$$= (\text{Normalized ppm [mg/L] fluorine} / \text{Mol Wt F [mg/mmol]}) \times \text{molar ratio active/F [mmol active/mmol F]} \times 1000 \text{ μmol/mmol}$$

Company Sanitized. Does not contain TSCA CBI

FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS

Considerations:

- The data used for kinetic analysis was from a limited screen and extrapolation should be done cautiously.
- Sample size is low
- Analytical data used without validation
- Steady-state not reached
- Terminal phase may not be reached
- Some compounds are mixtures of fluorinated compounds
- Different active and formulation doses were used
- Different vehicles were used to deliver formulations
- Each compound may have very different potency for producing toxicity

Assumptions: (May or may not be justified in all cases)

- Fluorine concentrations are linear with respect to dose
- Analytical method is appropriate for all types of compounds
- Elimination kinetics can be determined based on total fluorine rather than on concentrations of individual components
- Background Fluorine is 0.2 ppm
- % F data is the % Fluorine of the active (Fluorine containing component(s) in the formulation)
- Molecular weight is the molecular weight of the active component in the formulation

Company Sanitized. Does not contain TSCA CBI

APPENDIX D

Individual Fluorine Levels in Blood

Company Sanitized. Does not contain TSCA CBI

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
646910	1	2.6	2.4	11.93	36.92
646911	1	2.7	2.5	12.43	38.46
646912	1	2.5	2.3	11.43	35.38
646913	1	2.6	2.4	11.93	36.92
646914	1	2.6	2.4	11.93	36.92
Group I					
646910	5	30.1	29.9	148.60	460.00
646911	5	30.3	30.1	149.60	463.08
646912	5	31.3	31.1	154.57	478.46
646913	5	32.2	32.0	159.04	492.31
646914	5	32.7	32.5	161.53	500.00
Group I					
646910	10	71.5	71.3	354.36	1096.92
646911	10	70.5	70.3	349.39	1081.54
646912	10	66.9	66.7	331.50	1026.15
646913	10	62.5	62.3	309.63	958.46
646914	10	68.6	68.4	339.95	1052.31

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
646915	13	55.0	54.8	272.36	843.08
646916	13	55.3	55.1	273.85	847.69
646917	13	52.2	52.0	258.44	800.00
646918	13	53.8	53.6	266.39	824.62
646919	13	53.6	53.4	265.40	821.54
Group III					
646915	24	38.9	38.7	192.34	595.38
646916	24	43.8	43.6	216.69	670.77
646917	24	37.6	37.4	185.88	575.38
646918	24	35.4	35.2	174.94	541.54
646919	24	42.4	42.2	209.73	649.23
Group III					
646915	52	23.2	23.0	114.31	353.85
646916	52	20.3	20.1	99.90	309.23
646917	52	25.9	25.7	127.73	395.38
646918	52	24.9	24.7	122.76	380.00
646919	52	23.5	23.3	115.80	358.46
Group III					
646915	94	13.3	13.1	65.11	201.54
646916	94	11.7	11.5	57.16	176.92
646917	94	12.9	12.7	63.12	195.38
646918	94	11.0	10.8	53.68	166.15
646919	94	14.1	13.9	69.08	213.85

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
646921	1	10.6	10.4	22.15	75.36
646922	1	10.7	10.5	22.37	76.09
646923	1	9.2	9.0	19.17	65.22
646924	1	5.3	5.1	10.86	36.96
646925	1	11.2	11.0	23.43	79.71
Group I					
646921	5	78.7	78.5	167.21	568.84
646922	5	83.2	83.0	176.79	601.45
646923	5	77.0	76.8	163.58	556.52
646924	5	66.1	65.9	140.37	477.54
646925	5	69.6	69.4	147.82	502.90
Group I					
646921	10	63.0	62.8	133.76	455.07
646922	10	69.1	68.9	146.76	499.28
646923	10	60.3	60.1	128.01	435.51
646924	10	62.5	62.3	132.70	451.45
646925	10	53.9	53.7	114.38	389.13

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
646926	13	34.8	34.6	73.70	250.72
646927	13	30.0	29.8	63.47	215.94
646928	13	23.7	23.5	50.06	170.29
646929	13	33.7	33.5	71.36	242.75
646930	13	25.4	25.2	53.68	182.61
Group III					
646926	24	11.9	11.7	24.92	84.78
646927	24	10.4	10.2	21.73	73.91
646928	24	8.1	7.9	16.83	57.25
646929	24	15.7	15.5	33.02	112.32
646930	24	9.8	9.6	20.45	69.57
Group III					
646926	52	2.5	2.3	4.90	16.67
646927	52	1.7	1.5	3.20	10.87
646928	52	1.3	1.1	2.34	7.97
646929	52	4.0	3.8	8.09	27.54
646930	52	1.8	1.6	3.41	11.59
Group III					
646926	94	0.8	0.6	1.28	4.35
646927	94	<0.5	*	*	*
646928	94	<0.5	*	*	*
646929	94	0.9	0.7	1.49	5.07
646930	94	<0.5	*	*	*

* Below LOQ (Limit of Quantification)

Company Sanitized. Does not contain TSCA CBI

Data for H-24750

Given:

Mol Wt. Active (g/mole):	514	% F in Active:	70.2
Formulation Dose (mg/kg):	5	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	5	Molar Ratio (Active/F):	0.053
Dose Active (mmole/kg):	0.010	Dose F (mg/kg):	3.5
Dose F (mmol/kg):	0.185		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
665547	1	3.01	2.8	28.89	80.06
665548	1	3.25	3.1	31.36	86.89
665549	1	2.68	2.5	25.50	70.66
665550	1	3.21	3.0	30.95	85.75
665553	1	3.54	3.3	34.34	95.16
Group I					
665547	5	19.27	19.1	196.07	543.30
665548	5	15.37	15.2	155.97	432.19
665549	5	19.83	19.6	201.83	559.26
665550	5	15.47	15.3	157.00	435.04
665553	5	15.72	15.5	159.57	442.17
Group I					
665547	10	30.45	30.3	311.02	861.82
665548	10	28.9	28.7	295.08	817.66
665549	10	30.09	29.9	307.32	851.57
665550	10	30.44	30.2	310.92	861.54
665553	10	32.3	32.1	330.04	914.53

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
665554	13	46.92	46.7	480.36	1331.05
665555	13	31.35	31.2	320.27	887.46
665558	13	32.95	32.8	336.72	933.05
665559	13	30.2	30.0	308.45	854.70
665560	13	30.56	30.4	312.15	864.96
Group III					
665554	24	31.31	31.1	319.86	886.32
665555	24	25.29	25.1	257.97	714.81
665558	24	32.36	32.2	330.66	916.24
665559	24	26.8	26.6	273.49	757.83
665560	24	22.25	22.1	226.71	628.21
Group III					
665554	52	11.09	10.9	111.97	310.26
665555	52	7.64	7.4	76.50	211.97
665558	52	12.96	12.8	131.19	363.53
665559	52	8.88	8.7	89.24	247.29
665560	52	5.91	5.7	58.71	162.68
Group III					
665554	94	6.3	6.1	62.72	173.79
665555	94	6.28	6.1	62.51	173.22
665558	94	6.13	5.9	60.97	168.95
665559	94	6.9	6.7	68.89	190.88
665560	94	5.6	5.4	55.52	153.85

Company Sanitized. Does not contain TSCA CBI

APPENDIX E

Individual Fluorine Levels in Liver

Company Sanitized. Does not contain TSCA CBI

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
646910	10	320.9	320.7	1593.88	4933.85
646911	10	334.0	333.8	1658.99	5135.38
646912	10	318.6	318.4	1582.45	4898.46
646913	10	281.6	281.4	1398.56	4329.23
646914	10	306.6	306.4	1522.81	4713.85
Group III					
646915	94	85.6	85.4	424.44	1313.85
646916	94	75.9	75.7	376.23	1164.62
646917	94	87.5	87.3	433.88	1343.08
646918	94	78.0	77.8	386.67	1196.92
646919	94	94.2	94.0	467.18	1446.15

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
646921	10	118.3	118.1	251.55	855.80
646922	10	122.7	122.5	260.93	887.68
646923	10	114.3	114.1	243.03	826.81
646924	10	121.6	121.4	258.58	879.71
646925	10	122.1	121.9	259.65	883.33
Group III					
646926	94	1.8	1.6	3.41	11.59
646927	94	1.2	1.0	2.13	7.25
646928	94	2.2	2.0	4.26	14.49
646929	94	4.7	4.5	9.59	32.61
646930	94	2.9	2.7	5.75	19.57

Data for H-24750

Given:

Mol Wt. Active (g/mole):	514	% F in Active:	70.2
Formulation Dose (mg/kg):	5	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	5	Molar Ratio (Active/F):	0.053
Dose Active (mmole/kg):	0.010	Dose F (mg/kg):	3.5
Dose F (mmol/kg):	0.185		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
665547	10	186.4	186.2	1914.54	5305.13
665548	10	189.7	189.5	1948.47	5399.15
665549	10	200.5	200.3	2059.10	5705.70
665550	10	190.3	190.1	1954.84	5416.81
665553	10	202.6	202.4	2081.30	5767.24
Group III					
665554	94	57.33	57.1	587.39	1627.64
665555	94	49.65	49.5	508.43	1408.83
665558	94	57.97	57.8	593.97	1645.87
665559	94	48.41	48.2	495.68	1373.50
665560	94	46.68	46.5	477.89	1324.22

Company Sanitized. Does not contain TSCA CBI

APPENDIX F

Individual Fluorine Levels in Fat

Company Sanitized. Does not contain TSCA CBI

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
646910	10	14.4	14.2	70.57	218.46
646911	10	14.9	14.7	73.06	226.15
646912	10	10.9	10.7	53.18	164.62
646913	10	11.6	11.4	56.66	175.38
646914	10	12.4	12.2	60.63	187.69
Group III					
646915	94	1.3	1.1	5.47	16.92
646916	94	1.1	0.9	4.47	13.85
646917	94	1.3	1.1	5.47	16.92
646918	94	0.8	0.6	2.98	9.23
646919	94	1.5	1.3	6.46	20.00

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
646921	10	6.2	6.0	12.78	43.48
646922	10	8.5	8.3	17.68	60.14
646923	10	8.7	8.5	18.11	61.59
646924	10	8.8	8.6	18.32	62.32
646925	10	8.3	8.1	17.25	58.70
Group III					
646926	94	ND	ND	ND	ND
646927	94	ND	ND	ND	ND
646928	94	ND	ND	ND	ND
646929	94	ND	ND	ND	ND
646930	94	ND	ND	ND	ND

ND Non-detectable.

Company Sanitized. Does not contain TSCA CBI

Data for H-24750

Given:

Mol Wt. Active (g/mole):	514	% F in Active:	70.2
Formulation Dose (mg/kg):	5	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	5	Molar Ratio (Active/F):	0.053
Dose Active (mmole/kg):	0.010	Dose F (mg/kg):	3.5
Dose F (mmol/kg):	0.185		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
665547	10	4.21	4.0	41.23	114.25
665548	10	3.71	3.5	36.09	100.00
665549	10	2.79	2.6	26.63	73.79
665550	10	4.24	4.0	41.54	115.10
665553	10	3.45	3.3	33.42	92.59
Group III					
665554	94	<.5	*	*	*
665555	94	<.5	*	*	*
665558	94	<.5	*	*	*
665559	94	<.5	*	*	*
665560	94	<.5	*	*	*

* Below LOQ (Limit of Quantification)

Company Sanitized. Does not contain TSCA CB1